OTCPK:MKEA.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Mauna Kea Technologies SA operates as a medical device company. More Details


Snowflake Analysis

Slightly overvalued with limited growth.


Similar Companies

Share Price & News

How has Mauna Kea Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MKEA.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-17.2%

MKEA.F

-2.0%

US Medical Equipment

-1.9%

US Market


1 Year Return

n/a

MKEA.F

14.7%

US Medical Equipment

13.1%

US Market

Return vs Industry: Insufficient data to determine how MKEA.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how MKEA.F performed against the US Market.


Shareholder returns

MKEA.FIndustryMarket
7 Day-17.2%-2.0%-1.9%
30 Day-17.2%0.2%-2.9%
90 Dayn/a13.1%8.2%
1 Yearn/a15.7%14.7%15.7%13.1%
3 Year-67.6%-67.6%71.6%67.2%38.4%29.1%
5 Year-65.5%-65.5%145.9%127.4%89.3%68.0%

Price Volatility Vs. Market

How volatile is Mauna Kea Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Mauna Kea Technologies undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MKEA.F ($1.2) is trading below our estimate of fair value ($5.71)

Significantly Below Fair Value: MKEA.F is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MKEA.F is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: MKEA.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MKEA.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MKEA.F is overvalued based on its PB Ratio (136.4x) compared to the US Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is Mauna Kea Technologies forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

39.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MKEA.F is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MKEA.F is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MKEA.F is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MKEA.F's revenue (30.4% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: MKEA.F's revenue (30.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MKEA.F's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Mauna Kea Technologies performed over the past 5 years?

-1.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MKEA.F is currently unprofitable.

Growing Profit Margin: MKEA.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MKEA.F is unprofitable, and losses have increased over the past 5 years at a rate of 1.3% per year.

Accelerating Growth: Unable to compare MKEA.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MKEA.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).


Return on Equity

High ROE: MKEA.F has a negative Return on Equity (-6036.36%), as it is currently unprofitable.


Next Steps

Financial Health

How is Mauna Kea Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: MKEA.F's short term assets (€17.8M) exceed its short term liabilities (€7.6M).

Long Term Liabilities: MKEA.F's short term assets (€17.8M) exceed its long term liabilities (€15.8M).


Debt to Equity History and Analysis

Debt Level: MKEA.F's debt to equity ratio (6486.2%) is considered high.

Reducing Debt: MKEA.F's debt to equity ratio has increased from 17.9% to 6486.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MKEA.F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MKEA.F has less than a year of cash runway if free cash flow continues to grow at historical rates of 1.6% each year.


Next Steps

Dividend

What is Mauna Kea Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MKEA.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MKEA.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MKEA.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MKEA.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MKEA.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Rob Gershon (53 yo)

1.92yrs

Tenure

€825,498

Compensation

Mr. Robert L. Gershon, also known as Rob, has been Chief Executive Officer and Director at Mauna Kea Technologies SA since October 22, 2018. He served as the Chief Executive Officer of Bovie Medical Corpor ...


CEO Compensation Analysis

Compensation vs Market: Rob's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD601.34K).

Compensation vs Earnings: Insufficient data to compare Rob's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Alexandre Loiseau
Co-Founder & Chairman1.92yrs€639.30k1.68%
€ 678.6k
Robert Gershon
CEO & Director1.92yrs€825.50kno data
Christophe Lamboeuf
CFO & Deputy CEO2.42yrsno datano data
John Soto
Chief Operating Officer3.58yrsno datano data
François Lacombe
Chief Scientific Officerno datano datano data
Bruno Villaret
Global Director of Salesno datano datano data
John McCarthy
Chief Marketing Officer0.67yrno datano data
Nicolas Bouvier
Human Resources Directorno datano datano data
Aline Criton
Chief Clinical & Regulatory Affairs Officer0.67yrno datano data

2.2yrs

Average Tenure

53yo

Average Age

Experienced Management: MKEA.F's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Alexandre Loiseau
Co-Founder & Chairman1.92yrs€639.30k1.68%
€ 678.6k
Robert Gershon
CEO & Director1.92yrs€825.50kno data
Joseph Devivo
Independent & Non-Executive Director4.33yrs€42.78kno data
Molly O'Neill
Independent Director2.67yrs€33.56kno data
Christopher McFadden
Independent Director12.67yrsno datano data
Jennifer Tseng
Independent Director3.5yrsno datano data
Claire Biot
Independent Director0.17yrno datano data

2.7yrs

Average Tenure

53yo

Average Age

Experienced Board: MKEA.F's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.3%.


Top Shareholders

Company Information

Mauna Kea Technologies SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mauna Kea Technologies SA
  • Ticker: MKEA.F
  • Exchange: OTCPK
  • Founded: 2000
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €34.489m
  • Listing Market Cap: €40.470m
  • Shares outstanding: 30.52m
  • Website: https://www.maunakeatech.com

Number of Employees


Location

  • Mauna Kea Technologies SA
  • 9, rue d'Enghien
  • Paris
  • Ile-de-France
  • 75010
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MKEAENXTPA (Euronext Paris)YesOrdinary SharesFREURJul 2011
0P5ILSE (London Stock Exchange)YesOrdinary SharesGBEURJul 2011
MKEAPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJul 2011
MKEA.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2011
1MKDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2011

Biography

Mauna Kea Technologies SA operates as a medical device company. The company designs, develops, and markets various tools to visualize and detect cell abnormalities in real time during standard gastrointest ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/24 05:36
End of Day Share Price2020/09/22 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.